wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q37728232-A5EA77E3-292E-43C7-8FD4-703FF23E1716
Q37728232-A5EA77E3-292E-43C7-8FD4-703FF23E1716
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37728232-A5EA77E3-292E-43C7-8FD4-703FF23E1716
Low dosages: new chemotherapeutic weapons on the battlefield of immune-related disease.
P2860
Q37728232-A5EA77E3-292E-43C7-8FD4-703FF23E1716
BestRank
Statement
http://www.wikidata.org/entity/statement/Q37728232-A5EA77E3-292E-43C7-8FD4-703FF23E1716
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2cb9d2f17887d33d0d15d39f8c9c8619f77d008c
P2860
Phase II clinical trial results involving treatment with low-dose daily oral cyclophosphamide, weekly vinblastine, and rofecoxib in patients with advanced solid tumors.